Own manufacturing
Manufacturing expansion, proposed by March 2028
Strengthening quality control, supply-chain efficiency and the own-brand portfolio.
Aptus Pharma's strategic growth roadmap for 2028–2029, built on three pillars: own manufacturing, global expansion and Pan-India scale.
View the roadmapWay ahead
Our goal
To build a diversified multi-vertical pharmaceutical platform with a strong domestic footprint and a global presence, driving sustainable and profitable long-term growth.
Aptus Pharma Limited aims to evolve into an integrated pharmaceutical manufacturing and export-focused company. By 2028, the company targets own manufacturing, strengthening quality control, supply-chain efficiency and its own-brand portfolio. Alongside manufacturing, Aptus Pharma plans to build a global export presence and achieve a Pan-India footprint by 2029, creating three key growth pillars: Own Manufacturing, Global Expansion and Pan-India Scale.
Manufacturing expansion, proposed by March 2028
Strengthening quality control, supply-chain efficiency and the own-brand portfolio.
By March 2028
Asia
Africa
Latin America
Pan India by March 2029
A Pan-India footprint, alongside own manufacturing and global expansion.
This communication is being issued by Aptus Pharma ltd.("the Company") for general information purposes only. The information contained herein is based on management's current expectations and beliefs and is subject to change without notice. Certain statements in this document may be forward-looking in nature and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied. This document does not constitute or form part of any offer, invitation, or recommendation to purchase, hold, or sell any securities of the Company, nor shall any part of it form the basis of or be relied upon in connection with any contract or investment decision. The financial results referred to herein are prepared in accordance with applicable Indian Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and are subject to audit / limited review by the statutory auditors of the Company. Neither the Company nor its directors, officers, employees, or advisors accept any liability whatsoever for any loss or damage arising from the use of this information.
The Company undertakes no obligation to update any forward-looking statements or information contained herein to reflect subsequent events or circumstances, except as required under applicable law.
Explore further
See how Aptus Pharma's business is structured today, or get in touch with the team.